1 State's Plan to Fight the AIDS Epidemic

New York has a bold initiative underway to significantly decrease the number of HIV cases diagnosed every year by identifying those most at risk of contacting the disease, and prescribing PrEP therapy using Gilead's (GILD) Truvada.

Jul 6, 2014 at 1:30PM

The State of New York recently announced its bold plan to fight back against AIDS in a press release titled "Governor Cuomo Announces Plan to End the AIDS Epidemic in New York State." The goal is simple: make HIV so uncommon that the number of people diagnosed each year is as small as the number of people diagnosed with tuberculosis. New York's plan to effectively stamp out new cases of HIV is unique in a nation that has seen little change in the absolute number of people diagnosed with the disease during the past 20 years.

The state's trailblazing approach makes it a pioneer in building upon official guidelines issued in May by the Centers of Disease Control, or CDC, recommending the widespread use of Gilead's (NASDAQ:GILD) HIV drug Truvada as a pre-exposure prophylaxis, or PrEP, therapy. It's also likely to boost the use and adherence to drugs offered by a range of drugmakers including Gilead, Bristol-Myers Squibb (NYSE:BMY) and AbbVie (NYSE:ABBV)

Controlling the disease
New York's three-point plan aims to reduce the number of people diagnosed with HIV to a level below the number of people passing away annually from the disease by 2020. This plan includes actively finding those with the disease who have yet to be diagnosed, increasing the use of anti-HIV drugs for those who are already diagnosed, and expanding Truvada's use among those at risk of contracting HIV.

Accomplishing this plan requires far closer communication between the state and physicians, and a significant outreach program designed to educate individuals about Truvada's role in PrEP.

In trials leading up to Truvada's FDA approval in 2012, the drug reduced the chances of contracting HIV by up to 92%. Yet, despite that significant reduction, and sales of more than $750 million in the first quarter, Truvada is only now beginning to see widespread use -- thanks, in part, to the new CDC recommendations.


Source: CDC

If New York succeeds in identifying those most at risk for contracting the disease, and is able to get and keep them on Truvada, the state has a very good chance of building upon its already impressive track record. In the past 10 years, the number of people diagnosed each year with HIV in New York has fallen by 40%, an impressive statistic considering that the national rate hasn't budged from about 50,000 new cases per year.

Reaching the target
In order to achieve its goal, the state is casting aside onerous requirements for written consent to HIV testing in favor of the verbal consent that is typical for most other tests. New York has also orchestrated deals with drugmakers of widely used HIV medications, including Gilead, that represent 70% of the HIV treatment market.

Gilead markets a slate of HIV drugs, including Truvada, which combined, generate more than $9 billion a year in sales. While participating in New York's program will mean Gilead will receive less than the $14,000 annual price for Truvada, it's likely to mean thousands of new patients, and a chance to further establish the drug as a cornerstone of efforts to erase HIV nationally.

Bristol-Myers, the maker of Reyataz, an HIV drug with $344 million in first-quarter sales, and AbbVie, which markets Kaletra, an HIV treatment with revenue of nearly $200 million in the first quarter, have also agreed to price cuts with the state.

Fool-worthy final thoughts
In order to gain the maximum protection against HIV, patients prescribed Truvada will need to take the once-daily drug consistently and continuously for as long as they're at risk, and they'll need to follow up with physicians every three months for screening. That could pose challenges for the state in monitoring and maintaining adherence.

The stakes, however, for keeping at-risk patients on PrEP are high. New York estimates that, for every person it can keep from getting HIV, the state will save $400,000 on costs of care over their lifetimes. That has New York estimating that, by preventing 3,400 cases per year, it will save $317 million in health-care costs that it would otherwise spend without its aggressive plan.

If this plan succeeds, it'll be good news for investors -- Gilead, Bristol-Myers, and AbbVie will make more money for shareholders -- but more importantly, it'll be good for public health here in the United States as a model for other states as they take the offensive in the fight against HIV.

An even bigger public health opportunity for your portfolio?
Let me cut right to the chase. There's a product in development that will revolutionize not only how we treat a common chronic illness, but potentially the entire health industry -- leading to better health outcomes and strong profits for the companies investing in this technology. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing opportunity. CLICK HERE NOW.

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not own positions in the companies mentioned. The Motley Fool recommends Gilead Sciences. The Motley Fool owns shares of Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information